Selected research
Industry Research
Liposomal-based Drug Industry Research Report 2026
Market perspective
The global Liposomal-based Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Liposomal-based Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Liposomal-based Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Liposomal-based Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Liposomal-based Drug include Takeda, Teva, Sun Pharmaceutical, Johnson & Johnson, Chiesi Farmaceutici, Gilead Sciences, Zydus Cadila, TTY Biopharma and Sayre Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Liposomal-based Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Liposomal-based Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liposomal-based Drug Market by Company
Takeda
Teva
Sun Pharmaceutical
Johnson & Johnson
Chiesi Farmaceutici
Gilead Sciences
Zydus Cadila
TTY Biopharma
Sayre Therapeutics
Pacira
Luye Pharma
Leadiant Biosciences
Kinyond
Jazz
Ipsen
Fudan-Zhangjiang
CSPC
Bausch Health
Alnylam
Acrotech Biopharma
Liposomal-based Drug Segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Liposomal-based Drug Segment by Application
Hospital
Retail Pharmacy
Other
Liposomal-based Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposomal-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal-based Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Liposomal-based Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liposomes Drugs
- Lipid Nanoparticle Drugs
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Takeda
- Teva
- Sun Pharmaceutical
- Johnson & Johnson
- Chiesi Farmaceutici
- Gilead Sciences
- Zydus Cadila
- TTY Biopharma
- Sayre Therapeutics
- Pacira
- Luye Pharma
- Leadiant Biosciences
- Kinyond
- Jazz
- Ipsen
- Fudan-Zhangjiang
- CSPC
- Bausch Health
- Alnylam
- Acrotech Biopharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Liposomal-based Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Liposomes Drugs
- 2.2.3 Lipid Nanoparticle Drugs
- 2.3 Liposomal-based Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Liposomal-based Drug Breakdown Data by Type
- 3.1 Global Liposomal-based Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Liposomal-based Drug Forecasted Market Size by Type (2027-2032)
4 Liposomal-based Drug Breakdown Data by Application
- 4.1 Global Liposomal-based Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Liposomal-based Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Liposomal-based Drug Market Perspective (2021-2032)
- 5.2 Global Liposomal-based Drug Growth Trends by Region
- 5.2.1 Global Liposomal-based Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Liposomal-based Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Liposomal-based Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Liposomal-based Drug Market Dynamics
- 5.3.1 Liposomal-based Drug Industry Trends
- 5.3.2 Liposomal-based Drug Market Drivers
- 5.3.3 Liposomal-based Drug Market Challenges
- 5.3.4 Liposomal-based Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Liposomal-based Drug Players by Revenue
- 6.1.1 Global Top Liposomal-based Drug Players by Revenue (2021-2026)
- 6.1.2 Global Liposomal-based Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Liposomal-based Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Liposomal-based Drug Head Office and Area Served
- 6.4 Global Liposomal-based Drug Players, Product Type & Application
- 6.5 Global Liposomal-based Drug Manufacturers Established Date
- 6.6 Global Liposomal-based Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Liposomal-based Drug Market Size (2021-2032)
- 7.2 North America Liposomal-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Liposomal-based Drug Market Size by Country (2021-2026)
- 7.4 North America Liposomal-based Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Liposomal-based Drug Market Size (2021-2032)
- 8.2 Europe Liposomal-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Liposomal-based Drug Market Size by Country (2021-2026)
- 8.4 Europe Liposomal-based Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Liposomal-based Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Liposomal-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Liposomal-based Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Liposomal-based Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Liposomal-based Drug Market Size (2021-2032)
- 10.2 South America Liposomal-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Liposomal-based Drug Market Size by Country (2021-2026)
- 10.4 South America Liposomal-based Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Liposomal-based Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Liposomal-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Liposomal-based Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Liposomal-based Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Liposomal-based Drug Business (2021-2026)
- 12.1.4 Takeda Liposomal-based Drug Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Liposomal-based Drug Business (2021-2026)
- 12.2.4 Teva Liposomal-based Drug Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Sun Pharmaceutical
- 12.3.1 Sun Pharmaceutical Company Information
- 12.3.2 Sun Pharmaceutical Business Overview
- 12.3.3 Sun Pharmaceutical Revenue in Liposomal-based Drug Business (2021-2026)
- 12.3.4 Sun Pharmaceutical Liposomal-based Drug Product Portfolio
- 12.3.5 Sun Pharmaceutical Recent Developments
- 12.4 Johnson & Johnson
- 12.4.1 Johnson & Johnson Company Information
- 12.4.2 Johnson & Johnson Business Overview
- 12.4.3 Johnson & Johnson Revenue in Liposomal-based Drug Business (2021-2026)
- 12.4.4 Johnson & Johnson Liposomal-based Drug Product Portfolio
- 12.4.5 Johnson & Johnson Recent Developments
- 12.5 Chiesi Farmaceutici
- 12.5.1 Chiesi Farmaceutici Company Information
- 12.5.2 Chiesi Farmaceutici Business Overview
- 12.5.3 Chiesi Farmaceutici Revenue in Liposomal-based Drug Business (2021-2026)
- 12.5.4 Chiesi Farmaceutici Liposomal-based Drug Product Portfolio
- 12.5.5 Chiesi Farmaceutici Recent Developments
- 12.6 Gilead Sciences
- 12.6.1 Gilead Sciences Company Information
- 12.6.2 Gilead Sciences Business Overview
- 12.6.3 Gilead Sciences Revenue in Liposomal-based Drug Business (2021-2026)
- 12.6.4 Gilead Sciences Liposomal-based Drug Product Portfolio
- 12.6.5 Gilead Sciences Recent Developments
- 12.7 Zydus Cadila
- 12.7.1 Zydus Cadila Company Information
- 12.7.2 Zydus Cadila Business Overview
- 12.7.3 Zydus Cadila Revenue in Liposomal-based Drug Business (2021-2026)
- 12.7.4 Zydus Cadila Liposomal-based Drug Product Portfolio
- 12.7.5 Zydus Cadila Recent Developments
- 12.8 TTY Biopharma
- 12.8.1 TTY Biopharma Company Information
- 12.8.2 TTY Biopharma Business Overview
- 12.8.3 TTY Biopharma Revenue in Liposomal-based Drug Business (2021-2026)
- 12.8.4 TTY Biopharma Liposomal-based Drug Product Portfolio
- 12.8.5 TTY Biopharma Recent Developments
- 12.9 Sayre Therapeutics
- 12.9.1 Sayre Therapeutics Company Information
- 12.9.2 Sayre Therapeutics Business Overview
- 12.9.3 Sayre Therapeutics Revenue in Liposomal-based Drug Business (2021-2026)
- 12.9.4 Sayre Therapeutics Liposomal-based Drug Product Portfolio
- 12.9.5 Sayre Therapeutics Recent Developments
- 12.10 Pacira
- 12.10.1 Pacira Company Information
- 12.10.2 Pacira Business Overview
- 12.10.3 Pacira Revenue in Liposomal-based Drug Business (2021-2026)
- 12.10.4 Pacira Liposomal-based Drug Product Portfolio
- 12.10.5 Pacira Recent Developments
- 12.11 Luye Pharma
- 12.11.1 Luye Pharma Company Information
- 12.11.2 Luye Pharma Business Overview
- 12.11.3 Luye Pharma Revenue in Liposomal-based Drug Business (2021-2026)
- 12.11.4 Luye Pharma Liposomal-based Drug Product Portfolio
- 12.11.5 Luye Pharma Recent Developments
- 12.12 Leadiant Biosciences
- 12.12.1 Leadiant Biosciences Company Information
- 12.12.2 Leadiant Biosciences Business Overview
- 12.12.3 Leadiant Biosciences Revenue in Liposomal-based Drug Business (2021-2026)
- 12.12.4 Leadiant Biosciences Liposomal-based Drug Product Portfolio
- 12.12.5 Leadiant Biosciences Recent Developments
- 12.13 Kinyond
- 12.13.1 Kinyond Company Information
- 12.13.2 Kinyond Business Overview
- 12.13.3 Kinyond Revenue in Liposomal-based Drug Business (2021-2026)
- 12.13.4 Kinyond Liposomal-based Drug Product Portfolio
- 12.13.5 Kinyond Recent Developments
- 12.14 Jazz
- 12.14.1 Jazz Company Information
- 12.14.2 Jazz Business Overview
- 12.14.3 Jazz Revenue in Liposomal-based Drug Business (2021-2026)
- 12.14.4 Jazz Liposomal-based Drug Product Portfolio
- 12.14.5 Jazz Recent Developments
- 12.15 Ipsen
- 12.15.1 Ipsen Company Information
- 12.15.2 Ipsen Business Overview
- 12.15.3 Ipsen Revenue in Liposomal-based Drug Business (2021-2026)
- 12.15.4 Ipsen Liposomal-based Drug Product Portfolio
- 12.15.5 Ipsen Recent Developments
- 12.16 Fudan-Zhangjiang
- 12.16.1 Fudan-Zhangjiang Company Information
- 12.16.2 Fudan-Zhangjiang Business Overview
- 12.16.3 Fudan-Zhangjiang Revenue in Liposomal-based Drug Business (2021-2026)
- 12.16.4 Fudan-Zhangjiang Liposomal-based Drug Product Portfolio
- 12.16.5 Fudan-Zhangjiang Recent Developments
- 12.17 CSPC
- 12.17.1 CSPC Company Information
- 12.17.2 CSPC Business Overview
- 12.17.3 CSPC Revenue in Liposomal-based Drug Business (2021-2026)
- 12.17.4 CSPC Liposomal-based Drug Product Portfolio
- 12.17.5 CSPC Recent Developments
- 12.18 Bausch Health
- 12.18.1 Bausch Health Company Information
- 12.18.2 Bausch Health Business Overview
- 12.18.3 Bausch Health Revenue in Liposomal-based Drug Business (2021-2026)
- 12.18.4 Bausch Health Liposomal-based Drug Product Portfolio
- 12.18.5 Bausch Health Recent Developments
- 12.19 Alnylam
- 12.19.1 Alnylam Company Information
- 12.19.2 Alnylam Business Overview
- 12.19.3 Alnylam Revenue in Liposomal-based Drug Business (2021-2026)
- 12.19.4 Alnylam Liposomal-based Drug Product Portfolio
- 12.19.5 Alnylam Recent Developments
- 12.20 Acrotech Biopharma
- 12.20.1 Acrotech Biopharma Company Information
- 12.20.2 Acrotech Biopharma Business Overview
- 12.20.3 Acrotech Biopharma Revenue in Liposomal-based Drug Business (2021-2026)
- 12.20.4 Acrotech Biopharma Liposomal-based Drug Product Portfolio
- 12.20.5 Acrotech Biopharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst